Evercore ISI lowered the firm’s price target on Travere Therapeutics (TVTX) to $35 from $45 and keeps an Outperform rating on the shares. All eyes are on the FSGS PDUFA on January 13, 2026, given that this has “implications for the whole renal field,” according to the analyst, who sees this as an up 30%-35% or down 60%-65% event for Travere.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- FILSPARI Positioned as Foundational Therapy for IgAN Following KDIGO Guidelines and PROTECT Study Validation
- Target initiated, Nike upgraded: Wall Street’s top analyst calls
- Travere Therapeutics price target raised to $25 from $20 at Stifel
- Travere Therapeutics falls -6.6%
- Travere Therapeutics price target raised to $35 from $27 at Wells Fargo